Evidence map›Paper›PMID 32772817›Full record

ReviewGut microbes2020

Antimicrobial resistance in enteric bacteria: current state and next-generation solutions.

M J Wallace, S R S Fishbein, G Dantas

Open access · goldAbstract readReview
In one paragraph

Review in Gut microbes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Flavonoids Identified inMolecules (Basel, Switzerland) · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Observational
  12. Article
  13. Antimicrobial Use Survey and Detection of ESBL-Antibiotics (Basel, Switzerland) · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

M J WallaceDepartment of Pathology & Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine in St. Louis , St. Louis, MO, USA.ORCID 0000-0003-3036-4545
S R S FishbeinDepartment of Pathology & Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine in St. Louis , St. Louis, MO, USA.
G DantasDepartment of Pathology & Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine in St. Louis , St. Louis, MO, USA.ORCID 0000-0003-0455-8370
Washington University in St. Louis · US

Funding

Pediatric Gastroenterology Research Training ProgramT32DK077653 · NIDDK · WASHINGTON UNIVERSITY · PI PHILLIP I TARR · 2007 to 2026
$5.8M
MOLECULAR ONCOLOGY TRAINING GRANTT32CA113275 · NCI · WASHINGTON UNIVERSITY · PI Matthew J Walter · 2006 to 2026
$5.7M
Tunable therapeutic modulation of the gut microbiome by engineered probioticsR01AT009741 · NCCIH · WASHINGTON UNIVERSITY · PI DANTAS, GAUTAM, MOON, TAE SEOK · 2018 to 2022
$3.5M
STRUCTURAL, MECHANISTIC, & EVOLUTIONARY CHARACTERIZATION OF TETRACYCLINE DESTRUCTASESR01AI123394 · NIAID · WASHINGTON UNIVERSITY · PI DANTAS, GAUTAM, WENCEWICZ, TIMOTHY ADAM · 2016 to 2019
$2.7M
Occupational Exposure and Health Risk from Dairy Microbiome and Resistome to Dairy Farm WorkersR01OH011578 · OH · WASHINGTON UNIVERSITY · PI DANTAS, GAUTAM, SHUKLA, SANJAY K · 2018 to 2021
$2.0M
PEDIATRIC GASTROENTEROLOGY RESEARCH TRAININGT32HD007409 · NICHD · WASHINGTON UNIVERSITY · PI TARR, PHILLIP I · 1991 to 2005
$978k
NCI NIH HHS T32 CA113275NIAID NIH HHS R01 AI123394NICHD NIH HHS T32 HD007409NIDDK NIH HHS T32 DK077653NIOSH CDC HHS R01 OH011578
6 · The paper itself

Abstract

Antimicrobial resistance is one of the largest threats to global health and imposes substantial burdens in terms of morbidity, mortality, and economic costs. The gut is a key conduit for the genesis and spread of antimicrobial resistance in enteric bacterial pathogens. Distinct bacterial species that cause enteric disease can exist as invasive enteropathogens that immediately evoke gastrointestinal distress, or pathobionts that can arise from established bacterial commensals to inflict dysbiosis and disease. Furthermore, various environmental reservoirs and stressors facilitate the evolution and transmission of resistance. In this review, we present a comprehensive discussion on circulating resistance profiles and gene mobilization strategies of the most problematic species of enteric bacterial pathogens. Importantly, we present emerging approaches toward surveillance of pathogens and their resistance elements as well as promising treatment strategies that can circumvent common resistance mechanisms.

Indexed as

Drug Resistance, BacterialGastrointestinal MicrobiomeAnti-Bacterial AgentsBacteriaBiological EvolutionDysbiosisHigh-Throughput Nucleotide SequencingHumansInterspersed Repetitive SequencesMetagenomicsAnti-Bacterial AgentsAntimicrobial resistanceenteric pathogenhigh-throughput sequencingmetagenomicsmobile genetic elementpathobiontwhole-genome sequencing

Identifiers

PMID32772817
PMCPMC7524338
OpenAlexW3048389182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.